The Schaffhausen-based firm GENIUS Pharmaceutical AG has started selling a new antibody test by the name of GENmonitor, further details of which can be found in a press release. The test serves the purpose of detecting IgG antibodies, which are effective at neutralizing the SARS-CoV-2 spike protein. The test results therefore provide information regarding immunity from coronavirus following vaccination or recovery from illness.
The test can detect neutralizing antibodies in human plasma, serum or whole blood samples, delivering a result is just ten minutes. It was developed by Prima Lab based in the canton of Ticino.
GENmonitor is intended to support medical staff in making recommendations on further vaccination activity. “Developments such as in Australia or Singapore, where the number of cases is rising again despite decent vaccination rates, could be identified so that if the antibody titer is insufficient, re-vaccination can be carried out in the form of a booster jab”, comments Markus Neumann, medical-scientific advisor and responsible for the quality analysis of partner products at GENIUS Pharmaceutical.
GENIUS Pharmaceutical will initially launch the test in Switzerland in addition to Germany and Austria.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space